These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7495093)

  • 1. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants.
    Cadroy Y; Sié P; Alhenc-Gelas M; Aiach M
    Thromb Haemost; 1995 Apr; 73(4):734-5. PubMed ID: 7495093
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The significance of APC resistance (activated protein C) for clinical practice].
    Lämmle B; Demarmels Biasiutti F; Wuillemin WA; Stucki B; Furlan M
    Praxis (Bern 1994); 1997 Jan; 86(5):154-61. PubMed ID: 9064734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events. Vienna Thrombophilia in Stroke Study Group (VITISS).
    Halbmayer WM; Haushofer A; Angerer V; Finsterer J; Fischer M
    Blood Coagul Fibrinolysis; 1997 Sep; 8(6):361-4. PubMed ID: 9351526
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients.
    Freyburger G; Javorschi S; Labrouche S; Bernard P
    Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation in blood coagulation factor V associated with resistance to activated protein C.
    Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
    Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
    Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
    Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single point mutation at Arg506 of factor V associated with APC resistance and venous thromboembolism: improved detection by PCR-mediated site-directed mutagenesis.
    Rabès JP; Trossaert M; Conard J; Samama M; Giraudet P; Boileau C
    Thromb Haemost; 1995 Nov; 74(5):1379-80. PubMed ID: 8607126
    [No Abstract]   [Full Text] [Related]  

  • 17. Factor V: Q506 and a negative APC-resistance test.
    Keeling DM
    Thromb Haemost; 1995 Nov; 74(5):1380-1. PubMed ID: 8607127
    [No Abstract]   [Full Text] [Related]  

  • 18. APC-PCI complex concentration is higher in patients with previous venous thromboembolism with Factor V Leiden.
    Strandberg K; Stenflo J; Nilsson C; Svensson PJ
    J Thromb Haemost; 2005 Nov; 3(11):2578-80. PubMed ID: 16241958
    [No Abstract]   [Full Text] [Related]  

  • 19. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
    Tripodi A; Negri B; Bertina RM; Mannucci PM
    Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
    Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.